Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.57 |
| ▸ | HPGD | P15428 | 7/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.57 |
| ▸ | GAA | P10253 | 6/20 | 0.53 |
| ▸ | ACHE | P22303 | 5/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.53 |
| ▸ | CA12 | O43570 | 4/20 | 0.53 |
| ▸ | CA9 | Q16790 | 4/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | GLA | P06280 | 2/20 | 0.53 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.53 |
| ▸ | CASP1 | P29466 | 2/20 | 0.53 |
| ▸ | CASP7 | P55210 | 2/20 | 0.53 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ayapin SCHEMBL30171405 | 1.00 | KDM4E (0.57) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL6843275 | 0.89 | KDM4E (0.57) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL28994323 | 0.82 | ALDH1A1 (0.59) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL12075314 | 0.77 | KDM4E (0.65) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL3277376 | 0.75 | GAA (0.49) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL6664851 | 0.75 | ALDH1A1 (0.63) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL6664850 | 0.75 | ALDH1A1 (0.63) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| Dihydro-Obliquin SCHEMBL12062091 | 0.74 | ALDH1A1 (1.00) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL4740620 | 0.74 | GAA (0.48) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL15842745 | 0.74 | CA9 (0.59) | KDM4EALDH1A1HPGDHSD17B10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12215332-B2 | Method of increasing resistance against soybean rust in transgenic plants by increasing the scoparone | BASF PLANT SCIENCE COMPANY GMBH (DE) | 2025-02-04 | — | — | US | disclosed |
| EP-4479540-A1 | COUMARIN SYNTHESIS AND USES THEREOF | BASF SE (DE) | 2024-12-25 | — | — | EP | disclosed |
| US-20240384288-A1 | COUMARIN TRANSPORTERS AND USES THEREOF | BASF PLANT SCIENCE COMPANY GMBH (DE) | 2024-11-21 | — | — | US | disclosed |
| CN-118715324-A | Coumarin synthesis and application thereof | 巴斯夫欧洲公司 | 2024-09-27 | — | — | CN | disclosed |
| EP-4405378-A1 | COUMARIN TRANSPORTERS AND USES THEREOF | BASF Plant Science Company GmbH (DE) | 2024-07-31 | — | — | EP | disclosed |
| CN-117740961-A | Compound analysis method of liquorice and liquorice probiotics fermentation preparation | 北京中医药大学 | 2024-03-22 | — | — | CN | disclosed |
| WO-2023156270-A1 | COUMARIN SYNTHESIS AND USES THEREOF | BASF SE (DE) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023150072-A1 | COMPOSITIONS AND METHODS FOR THE PRESERVATION OF PLANT MATTER | SINCLAIR DAVID A (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023041649-A1 | COUMARIN TRANSPORTERS AND USES THEREOF | BASF PLANT SCIENCE COMPANY GMBH (DE) | 2023-03-23 | — | — | WO | disclosed |
| US-20230022475-A1 | METHOD OF INCREASING RESISTANCE AGAINST SOYBEAN RUST IN TRANSGENIC PLANTS BY INCREASING THE SCOPARONE | BASF PLANT SCIENCE COMPANY GMBH (DE) | 2023-01-26 | — | — | US | disclosed |
| US-20040049056-A1 | Process for preparation of esculetin compounds, esculetin compounds and intermediates thereof, and use of both | KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1357118-A1 | PROCESS FOR PREPARATION OF ESCULETIN COMPOUNDS, ESCULETIN COMPOUNDS AND INTERMEDIATES THEREOF, AND USE OF BOTH | Kureha Chemical Industry Co., Ltd. (JP) | 2003-10-29 | — | — | EP | disclosed |
| JP-2003267964-A | METHOD FOR PRODUCING 6,7-DIHYDROXYCOUMARIN AND ITS INTERMEDIATE | UBE IND LTD | 2003-09-25 | — | — | JP | disclosed |
| JP-2003238553-A | 3-CHLORO-6,7-DIHYDROXYCOUMARIN AND METHOD FOR PRODUCING THE SAME | UBE IND LTD | 2003-08-27 | — | — | JP | disclosed |
| EP-0850221-B1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | SEARLE & CO (US) | 2001-07-18 | — | — | EP | disclosed |
| US-6028223-A | AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS | G. D. SEARLE & CO. (US) | 2000-02-22 | — | — | US | disclosed |
| US-5958782-A | FLUORESCENT IONOPHORIC COMPOUND IS DISCLOSED THAT INCLUDES A COMPLEXING MOIETY, SUCH AS A CRYPTAND OR CROWN-ETHER PORTION, AND A FLUORESCING MOIETY SUCH AS A COUMARIN PORTION | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1999-09-28 | — | — | US | disclosed |
| EP-0861843-A2 | Fluorescent ionophoric compounds with a cryptand/crown-ether portion and a coumarin portion, their preparation and their use for measuring metal cation concentrations | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1998-09-02 | — | — | EP | disclosed |
| EP-0850221-A1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1998-07-01 | — | — | EP | disclosed |
| WO-1997008145-A1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1997-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040049056-A1 | Process for preparation of esculetin compounds, esculetin compounds and intermediates thereof, and use of both | SUCLG1, SALL4, HSD17B14 | KDM4E 1966/4885ALDH1A1 71/4885HPGD 886/4885 |
| US-12215332-B2 | Method of increasing resistance against soybean rust in transgenic plants by increasing the scoparone | TPST2, SOAT2, ACAT2 | KDM4E 3604/4885ALDH1A1 4118/4885HPGD 3459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.